MENU
BBOT
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

BridgeBio Oncology Therapeutics (BBOT) Ownership - Who owns BridgeBio Oncology Therapeutics?

BridgeBio Oncology Therapeutics Inc, formerly BridgeBio Oncology Therapeutics is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes... Show more

Details

Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
920.67M
P/E Ratio
N/A
Total Cash
468.29M
Projected Growth
N/A
Total Debt
2.89M
Revenue
N/A
Risk (Beta)
N/A
Dividend Yield
N/A
Total Cash/Share
5.85
Total Debt/Equity
N/A
Revenue/Share
null USD as % of share price

Fundamentals

BBOT
Capitalization
921M
P/E Ratio
N/A
Risk (Beta)
N/A
Dividend Yield
N/A
Total Cash
468M
Total Cash/Share
5.85
Total Debt
2.89M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0%
Revenue
0
ROE
N/A
Book Value
447M
P/B Ratio
2.06
Cash Flow
N/A
Earnings
-1.45
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
8K
Current Ratio
13.33
Current Revenue Per Employee
N/A
Dividends Per Share - Security
N/A
EBITDA
-123.82M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-23.71
Shares Held By Institutions
680M
Shares Outstanding - Current
80M
Total Liabilities
38.1M
Total Volume MTD
N/A
Value
1
Gain YTD
-8.067
View a ticker or compare two or three
BBOT
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details